{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:34:34Z","timestamp":1766752474759,"version":"3.48.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to evaluate the surgical outcomes and prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in patients with molecularly confirmed oligodendrogliomas focussing on the extent of resection (EOR) and volumetric analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 115 adult patients with oligodendroglioma at our institution from January 2010 to December 2020. Inclusion criteria encompassed histologically and molecularly confirmed grade 2 and 3 oligodendroglioma, age above 18 years, availability of pre- and postoperative imaging, and complete follow-up data. Surgical outcomes were categorized by EOR and volumetric assessments were performed using neuroimaging. Mean OS and PFS were calculated using the Kaplan\u2013Meier method (As mortality was\u2005&amp;lt;\u200550%) and univariate\/multivariate analyses were conducted to identify prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort had a median age of 42 years (range 18-77), with GTR achieved in 47% of primary operations. Median follow-up was 6.3 years. OS was significantly influenced by age (p\u2005&amp;lt;\u20050.0001) and EOR, with a mean OS of 134 months and a mean PFS of 117 months. Volumetric reduction of tumor volume greater than 80% correlated positively with both OS and PFS. The analysis also highlighted the importance of adjuvant therapy in improving PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that younger age, extensive volumetric reduction, and intraoperative adjuncts are associated with improved OS and PFS in patients with oligodendroglioma. While the EOR impacts OS significantly in grade 3 tumors, further research is necessary to determine optimal surgical strategies for grade 2 oligodendrogliomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npaf052","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:24:01Z","timestamp":1748244241000},"page":"1058-1068","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of outcomes of patients with oligodendroglioma with focus on volumetric reduction"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-204X","authenticated-orcid":false,"given":"Salman T","family":"Shaikh","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mueez","family":"Waqar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yatharth","family":"Verma","sequence":"additional","affiliation":[{"name":"University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"Balogun","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Neurosurgery, College of Medicine, University of Ibadan , Ibadan ,","place":["Nigeria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"MacArthur","sequence":"additional","affiliation":[{"name":"University of Manchester , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Maye","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bailey","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Karabatsou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Djoukhadar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"McBain","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Manchester Academic Health Science Centre, The University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Clinical Oncology, The Christie NHS Foundation Trust , Manchester,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rovel","family":"Colaco","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerben","family":"Borst","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Geoffrey Jefferson Brain Research Centre, Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester , Salford ,","place":["UK"]},{"name":"Division of Cancer Sciences, Faculty of Biology, Medicines and Health, University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Clinical Oncology, The Christie NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Roncaroli","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Geoffrey Jefferson Brain Research Centre, Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-3938","authenticated-orcid":false,"given":"Pietro","family":"D\u2019Urso","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Manchester Academic Health Science Centre, The University of Manchester , Manchester ,","place":["UK"]},{"name":"Department of Neurosurgery, Salford Royal Hospital, Manchester Centre for Clinical Neurosciences , Salford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"8","key":"2025122607321167800_CIT0001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025122607321167800_CIT0002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00401-015-1424-1","article-title":"Oligodendroglioma: pathology, molecular mechanisms and markers","volume":"129","author":"Wesseling","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2025122607321167800_CIT0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jnen\/64.6.479","article-title":"Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas","volume":"64","author":"Ohgaki","year":"2005","journal-title":"J Neuropathol Exp Neurol."},{"issue":"7","key":"2025122607321167800_CIT0004","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.54.7.1442","article-title":"Long-term outcome of low-grade oligodendroglioma and mixed glioma","volume":"54","author":"Olson","year":"2000","journal-title":"Neurology."},{"issue":"5","key":"2025122607321167800_CIT0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s004010050830","article-title":"Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases","volume":"95","author":"Dehghani","year":"1998","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2025122607321167800_CIT0006","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas [published correction appears in Lancet Oncol","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"2025122607321167800_CIT0007","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and Oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J Clin Oncol."},{"issue":"8","key":"2025122607321167800_CIT0008","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol."},{"issue":"6","key":"2025122607321167800_CIT0009","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"van den Bent","year":"2011","journal-title":"Lancet Oncol."},{"issue":"22","key":"2025122607321167800_CIT0010","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.3390\/cancers14225705","article-title":"Review of intraoperative adjuncts for maximal safe resection of gliomas and its impact on outcomes","volume":"14","author":"Chanbour","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025122607321167800_CIT0011","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/BF01411993","article-title":"Prognostic factors in oligodendrogliomas","volume":"139","author":"Westergaard","year":"1997","journal-title":"Acta Neurochir (Wien)."},{"issue":"3","key":"2025122607321167800_CIT0012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnen\/60.3.248","article-title":"Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading","volume":"60","author":"Giannini","year":"2001","journal-title":"J Neuropathol Exp Neurol."},{"issue":"4","key":"2025122607321167800_CIT0013","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S0317167100032984","article-title":"Prognostic factors in oligodendroglioma","volume":"24","author":"Schiffer","year":"1997","journal-title":"Can J Neurol Sci."},{"issue":"13","key":"2025122607321167800_CIT0014","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.7314\/APJCP.2015.16.13.5319","article-title":"Prognostic factors in Oligodendrogliomas: a clinical study of twenty-five consecutive patients","volume":"16","author":"Atalay","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"issue":"3","key":"2025122607321167800_CIT0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1754-9485.2009.02074.x","article-title":"Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works","volume":"53","author":"Capelle","year":"2009","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2025122607321167800_CIT0016","doi-asserted-by":"crossref","first-page":"803975","DOI":"10.3389\/fonc.2021.803975","article-title":"WHO grade loses its prognostic value in molecularly defined diffuse lower-grade gliomas","volume":"11","author":"Carstam","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"2025122607321167800_CIT0017","first-page":"451","article-title":"Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma","volume":"6","author":"Gittleman","year":"2019","journal-title":"Neurooncol. Pract."},{"issue":"1","key":"2025122607321167800_CIT0018","doi-asserted-by":"crossref","first-page":"e0211513","DOI":"10.1371\/journal.pone.0211513","article-title":"Prognostic factors associated with survival in patients with anaplastic oligodendroglioma","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One."},{"issue":"2","key":"2025122607321167800_CIT0019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-016-2110-4","article-title":"Maximizing safe resection of low- and high-grade glioma","volume":"130","author":"Hervey-Jumper","year":"2016","journal-title":"J Neurooncol."},{"issue":"3","key":"2025122607321167800_CIT0020","first-page":"369","article-title":"Predictors and early survival outcomes of maximal resection in WHO grade II 1p\/19q-codeleted oligodendrogliomas","volume":"22","author":"Harary","year":"2020","journal-title":"Neuro Oncol"},{"issue":"9","key":"2025122607321167800_CIT0021","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","article-title":"The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a review by the RANO resect group","volume":"25","author":"Karschnia","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"2025122607321167800_CIT0022","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3171\/2020.2.JNS192767","article-title":"Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas [published correction appears in J Neurosurg. 2020 Jun 05;134(5):1675]","volume":"134","author":"Garton","year":"2020","journal-title":"J Neurosurg."},{"key":"2025122607321167800_CIT0023","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/j.wneu.2021.04.122","article-title":"Clinical characteristics and overall survival prognostic nomogram for Oligodendroglioma: a surveillance, epidemiology, and end results population-based analysis","volume":"151","author":"Cao","year":"2021","journal-title":"World Neurosurg"},{"issue":"12","key":"2025122607321167800_CIT0024","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1002\/cam4.1853","article-title":"The effects of tumor size and postoperative radiotherapy for patients with adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma\/oligodendroglioma: a population-based and propensity score matched study","volume":"7","author":"Lin","year":"2018","journal-title":"Cancer Med"},{"issue":"6","key":"2025122607321167800_CIT0025","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3171\/2012.2.JNS102032","article-title":"Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors","volume":"116","author":"Sankar","year":"2012","journal-title":"J Neurosurg."},{"issue":"1","key":"2025122607321167800_CIT0026","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/neuonc\/not159","article-title":"IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection","volume":"16","author":"Beiko","year":"2014","journal-title":"Neuro Oncol"},{"issue":"7","key":"2025122607321167800_CIT0027","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/neuonc\/noaa022","article-title":"Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p\/19q-codeleted oligodendrogliomas in adults","volume":"22","author":"Roux","year":"2020","journal-title":"Neuro Oncol"},{"issue":"14","key":"2025122607321167800_CIT0028","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"key":"2025122607321167800_CIT0029","doi-asserted-by":"crossref","first-page":"106303","DOI":"10.1016\/j.clineuro.2020.106303","article-title":"Anaplastic Oligodendroglioma - is adjuvant radiotherapy mandatory following maximal surgical resection? Grade 3 Oligo radiotherapy","volume":"200","author":"Profyris","year":"2021","journal-title":"Clin Neurol Neurosurg."},{"issue":"9490","key":"2025122607321167800_CIT0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial [published correction appears in Lancet. 2006 Jun 3;367(9525):1818]","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet."},{"issue":"5","key":"2025122607321167800_CIT0031","first-page":"CD007104","article-title":"Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas","volume":"2014","author":"Lecavalier-Barsoum","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"2025122607321167800_CIT0032","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11060-019-03261-5","article-title":"Extent of resection and survival for oligodendroglioma: a U.S. population-based study","volume":"144","author":"Kinslow","year":"2019","journal-title":"J Neurooncol."},{"issue":"4","key":"2025122607321167800_CIT0033","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3171\/2023.2.JNS222755","article-title":"Surgical, functional, and oncological considerations regarding awake resection for giant diffuse lower-grade glioma of more than 100 cm3","volume":"139","author":"Sauvageot","year":"2023","journal-title":"J Neurosurg."},{"issue":"1","key":"2025122607321167800_CIT0034","first-page":"vdae189","article-title":"Watch-and-wait approach versus adjuvant treatment after radical awake resection in selected adult-type grade 3 gliomas, isocitrate dehydrogenase mutant: a case-matched cohort","volume":"6","author":"Elia","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"2025122607321167800_CIT0035","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/j.wneu.2017.10.172","article-title":"Low-Grade glioma with foci of early transformation does not necessarily require adjuvant therapy after radical surgical resection","volume":"110","author":"Al-Tamimi","year":"2018","journal-title":"World Neurosurg."},{"issue":"8","key":"2025122607321167800_CIT0036","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1212\/WNL.0000000000008877","article-title":"Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III\/IV foci","volume":"94","author":"Darlix","year":"2020","journal-title":"Neurology."},{"issue":"3","key":"2025122607321167800_CIT0037","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/cco.2017.06.11","article-title":"Isocitrate dehydrogenase mutation as a therapeutic target in gliomas","volume":"6","author":"Han","year":"2017","journal-title":"Chin Clin Oncol"},{"issue":"7","key":"2025122607321167800_CIT0038","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf052\/63393721\/npaf052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/6\/1058\/63393721\/npaf052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/6\/1058\/63393721\/npaf052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:32:28Z","timestamp":1766752348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/6\/1058\/8152345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf052","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,5,28]]}}}